BIOSITE TO EXPAND TRIAGE SALES AND MARKETING ACTIVITIES, INCLUDING IN-HOUSE CAPABILITIES, WITH IPO PROCEEDS; EXPECTS TO RAISE $22-26 MIL. FROM OFFERING
This article was originally published in The Gray Sheet
Executive SummaryBiosite Diagnostics plans to use $7 mil. of proceeds from its initial public offering to expand its sales and marketing activities, including "the development of direct sales capabilities in select markets," the firm says in a Dec. 11 registration statement. The Securities and Exchange Commission filing covers a proposed IPO of 2 mil. shares that would raise $21.6 mil. in net proceeds at $12 a share.
You may also be interested in...
Dr Reddy’s sees its Indian domestic market and China as hot prospects as it pursues its “transformation journey” in which it is reducing its dependence on the slowing US market.
Glenmark has struck a deal with private equity firm True North for its gynecology business in India and Nepal.